以上内容基于公开资料整理，不构成投资建议。 经济观察网永顺生物在投资者互动平台披露，2025年上半年直销收入占比为33.14%，鸽新城疫灭活疫 苗已上市销售，猪伪狂犬病耐热保护剂活疫苗处于上市前筹备阶段。融资余额近期呈下降趋势，反映短 期资金观望情绪。 近7个交易日，永顺生物股价区间振幅2.82%，整体小幅震荡。2月12日收盘报9.01元，单日下跌2.38%。 期间股价最高为9.45元，最低为9.00元，资金面呈现融资余额连续下降趋势。 股票近期走势 ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

每经讯，2026年1月27日，北交所上市公司永顺生物（920729，收盘价：10.95元）登上龙虎榜，交易方式是连续竞价，披露原因 是当日换手率达到30.52%，成交数量2344.63万股，成交金额2.45亿元。买一席位为东方财富证券股份有限公司拉萨东环路第二 证券营业部，买入739.89万元；卖一席位为光大证券股份有限公司北京总部基地营业部，卖出610.51万元。 （记者 曾健辉） | | 2026-01-27永顺生物 (920729) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | ਜੇਟ ਹ | 东方财富证券股份有限公司拉萨东环路第二证券营业部 | 7398892.82 | 2833297.74 | | 买2 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | 5315437.55 | 2509545.89 | | 址3 | 国信证券股份有限公司深圳互联网分公司 | 4244010.63 | 2950816.6 | | 买4 | 中国银河证券股份有限公司北京远大路证券营业部 | 4208473.1 ...

Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Core Viewpoint - The animal health sector experienced a rise of 1.55% on January 9, with significant contributions from leading stocks like Biological Shares, which surged by 4.76% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4120.43, up by 0.92%, while the Shenzhen Component Index closed at 14120.15, up by 1.15% [1]. - The top-performing stock in the animal health sector was Biological Shares (600201), closing at 17.40 with a gain of 4.76% and a trading volume of 683,900 shares, amounting to a transaction value of 1.179 billion yuan [1]. Group 2: Stock Performance Summary - Other notable stocks included: - Shunlian Biological (688098) at 9.67, up by 1.90% with a trading volume of 64,900 shares [1]. - Zhongmu Shares (600195) at 8.10, up by 1.25% with a trading volume of 138,100 shares [1]. - Ruipu Biological (300119) at 19.90, up by 1.12% with a trading volume of 154,700 shares [1]. - Haili Biological (603718) at 6.48, up by 0.78% with a trading volume of 124,600 shares [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 27.3879 million yuan from institutional investors, while retail investors contributed a net inflow of 90.8993 million yuan [2]. - The capital flow for specific stocks showed: - Haili Biological had a net inflow of 10.2913 million yuan from institutional investors [3]. - Jinhe Biological experienced a net inflow of 2.8449 million yuan from institutional investors [3]. - *ST Green Kang (002868) had a net inflow of 1.8780 million yuan from institutional investors [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

Group 1 - The core point of the news is that Yongshun Biological (920729) has seen a net financing inflow of 25.57 million yuan on October 29, 2025, with a total financing balance of 1,300.67 million yuan, indicating a positive trend in investor interest [1][2][3] - Over the past three trading days, the cumulative net buying has reached 57.1 million yuan, reflecting a consistent increase in financing activity [1] - The financing balance increased by 2.01% compared to the previous day, showing a growing confidence among investors [2][3] Group 2 - The financing net buying on October 28 was 11,700 yuan, and on October 27, it was 303,600 yuan, indicating fluctuations in investor activity [2] - The financing balance on October 24 was 1,243.57 million yuan, which decreased by 21,170 yuan, highlighting a brief period of reduced investor engagement [2][3] - The overall margin trading balance on October 29 was 1,300.67 million yuan, marking a significant increase in trading activity [3]

Core Viewpoint - Yongshun Biological has demonstrated strong operational resilience with a slight increase in net profit despite a decrease in revenue, indicating effective cost control and product optimization strategies [1][2]. Financial Performance - In the first three quarters of 2025, Yongshun Biological achieved operating revenue of 180 million yuan, with a net profit attributable to shareholders of 30.28 million yuan, reflecting a year-on-year growth of 4.56% [1]. - The company's operating income decreased by 10.18% year-on-year, attributed to the cyclical fluctuations in the pig farming industry [2]. - The net cash flow from operating activities reached 74.66 million yuan, a significant increase of 34.97% year-on-year, indicating strong cash flow management [2]. - Asset impairment losses were reduced by 75.49% year-on-year, primarily due to improved inventory turnover and efficiency [2]. Product Development and Innovation - Yongshun Biological has focused on innovation, investing 15.31 million yuan in R&D, which is approximately 8.50% of its operating revenue [3]. - The company has recently obtained production licenses for two significant products: a quadrivalent inactivated vaccine for avian influenza and a bivalent inactivated vaccine for H5 subtype avian influenza, enhancing its market position in poultry vaccines [3]. - Additional product approvals include a new vaccine for pigeon newcastle disease and several other vaccines for swine diseases, indicating a robust pipeline for future growth [3]. Industry Outlook - The pig farming industry is expected to rebound in the fourth quarter, supported by policy adjustments and market corrections, positioning Yongshun Biological favorably for sustained growth in the upcoming industry cycle [4].

Market Overview - The animal health sector increased by 0.81% on October 20, with Xianfeng Holdings leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Xianfeng Holdings (002141) closed at 4.06, up 5.45% with a trading volume of 588,700 shares and a turnover of 237 million yuan [1] - Other notable stocks included ST Lvkang (002868) at 28.36, up 5.00%, and Biological Shares (600201) at 10.95, up 1.48% [1] - The overall trading volume and turnover for the animal health sector were significant, indicating active market participation [1] Capital Flow - The animal health sector saw a net inflow of 31.5863 million yuan from institutional investors, while retail investors experienced a net outflow of 10.9434 million yuan [2] - The main capital inflow was primarily directed towards Xianfeng Holdings, which had a net inflow of 28.5381 million yuan [3] - Conversely, stocks like Shunlian Biological (688088) and ST Lvkang experienced net outflows from retail investors, indicating a shift in investor sentiment [3]